The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies

Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immune response against NHL.

This podcast features experts Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, who discusses the future of CAR-T therapy and the risk of secondary malignancies, and Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, who gives an overview of the currently approved CAR-T products and bispecific antibodies in large B-cell lymphoma, and the optimal sequencing of these agents. 

The post The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies appeared first on VJHemOnc.